<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this study, we attempted to evaluate the clinical significance of T helper 1 (Th1)/T helper 2 (Th2) ratio in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), five refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA), four refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 31 refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>), nine refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blast-1 (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>) and seven refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess blast-2 (<z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Intracellular interleukin-4 (Th2 cytokine) and interferon-gamma (Th1 cytokine) production was assessed in CD4+ T lymphocytes activated by <z:chebi fb="0" ids="8116">phorbol</z:chebi> 12-<z:chebi fb="0" ids="30807">myristate</z:chebi> 13-<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> and ionomycin using flow cytometry </plain></SENT>
<SENT sid="2" pm="."><plain>Mean Th1/Th2 ratios in each <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> group were as follows: RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, 8.8 (95% CI, 5.8-11.8), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, 14.7 (95% CI, 9.5-19.9), <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>, 10.6 (95% CI, 4.6-16.6), <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e>, 12.8 (95% CI, 3.0-22.7) and control 12.8 (95% CI, 9.6-16.1) </plain></SENT>
<SENT sid="3" pm="."><plain>There were no significant differences in Th1/Th2 ratio in the RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e> and <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e> subgroups when compared to controls </plain></SENT>
<SENT sid="4" pm="."><plain>Because Th1/Th2 ratio in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> group was widely distributed, we divided <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> patients according to Th1/Th2 ratio into three groups (low, <z:mpath ids='MPATH_458'>normal</z:mpath> and high Th1/Th2 groups) </plain></SENT>
<SENT sid="5" pm="."><plain>There were no differences in severity of cytopenia among the three above groups </plain></SENT>
<SENT sid="6" pm="."><plain>However, the percentage of CD8 cells in the low Th1/Th2 group was significantly lower than those in the high group (P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>These data suggest that Th1/Th2 imbalance induces CD4/CD8 imbalance, and serves as a marker of the biological interplay in immune regulation </plain></SENT>
</text></document>